Clinical relevance of SUMOylation pathway in AML. (A) Kaplan-Meier curves with 95% confidence intervals (dotted lines) for overall survival of patients with AML in OHSU, according to the gene expression levels of UBA2 or SUMO1. The division of the high- and low-expression groups was determined by the best risk separation approach. (B) Comparison of UBA2, SUMO1, and SAE1 gene expression across healthy and ELN2017 risk groups. P values are from Jonckheere-Terpstra test. Subsequent post hoc analyses were performed with the two-stage linear step-up procedure, and the significance is indicated for each comparison. The number of participants is indicated for each group. (C) Comparison of UBE2I and SUMO1 gene expression between mutated and wild-type of NPM1, TP53, and RUNX1 genes in OHSU database. P values are from Wilcoxon rank-sum test. For panels B-C, ∗P < .05, ∗∗P < .01, ∗∗∗P < .001, ∗∗∗∗P < .0001. Adv, adverse; Fav, favorable; HR(high), hazard ratio of high expression group; Int, intermediate; ns, not significant.